Mark Chin - Oct 13, 2021 Form 4 Insider Report for Pyxis Oncology, Inc. (PYXS)

Role: Director
Signature: /s/ Pamela Connealy, Attorney-in-Fact for Mark Chin
Stock symbol: PYXS
Transactions as of: Oct 13, 2021
Transactions value $: $5,000,000
Form type: 4
Date filed: 10/15/2021, 05:37 PM
Previous filing: Oct 7, 2021
Next filing: Apr 4, 2022

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	PYXS	Common Stock	Conversion of derivative security		+1.43M			1.43M	Oct 13, 2021	See footnote	F1, F2
transaction	PYXS	Common Stock	Purchase	$5M	+313K	+21.8%	$16.00^*	1.75M	Oct 13, 2021	See footnote	F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	PYXS	Series B Convertible Preferred Stock	Conversion of derivative security	$0	-9.11M	-100%	$0.00^*	0	Oct 13, 2021	Common Stock	1.43M		See footnote	F1, F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	These shares of Series B Convertible Preferred Stock converted automatically and for no additional consideration into Common Stock on a 6.359-for-1 basis upon completion of the Issuer's initial public offering (with fractional shares paid out in cash). The shares of Series B Convertible Preferred Stock had no expiration date.
F2	These securities are held directly by Arix Bioscience Holdings Limited ("Arix"). The reporting person is one of four members of the Investment Committee of Arix and, in such capacity, may be deemed to share voting and dispositive power over the securities held by Arix. The reporting person disclaims beneficial ownership of such securities except to the extent of his respective pecuniary interests therein.

Content

These shares of Series B Convertible Preferred Stock converted automatically and for no additional consideration into Common Stock on a 6.359-for-1 basis upon completion of the Issuer's initial public offering (with fractional shares paid out in cash). The shares of Series B Convertible Preferred Stock had no expiration date.

These securities are held directly by Arix Bioscience Holdings Limited ("Arix"). The reporting person is one of four members of the Investment Committee of Arix and, in such capacity, may be deemed to share voting and dispositive power over the securities held by Arix. The reporting person disclaims beneficial ownership of such securities except to the extent of his respective pecuniary interests therein.